Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2023 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe the company as currently living through a defined waiting period it is paying for out of its own pocket — that is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward? We need to find if management describes such a situation. The transcript discusses the FDA De Novo denial and appeal. They filed an appeal, expect response by end of January 2024. They are waiting for that. But is that a "waiting period" they are paying for? They are incurring costs? They mention R&D expenses, sales and marketing, etc. But the specific phenomenon: paying now for something not yet earning, with a specific near-dated event. The appeal is a regulatory process, not necessarily a cost they are bearing. They are not paying for the FDA review. They are waiting for a response. But the question is about a "defined waiting period it is paying for out of its own pocket" — meaning they are incurring costs for something that hasn't yielded yet. For example, they have sales and marketing expenses in anticipation of U.S. commercial sales infrastructure. They mention "in support of ongoing global commercialization adoption and in anticipation of enhancing our U.S. commercial sales infrastructure, sales and marketing expenses increased." That could be paying for future benefit. But is that a defined waiting period with a specific near-dated event? They also mention the ICE3 study completion expected in Q1 2024. They are waiting for that. But is that a cost they are bearing? The study is ongoing, they are funding it. The benefit would be FDA approval. But the appeal response is end of January. The study completion is Q1 2024. They plan to submit for entire study by summer 2024. But the question asks: "the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet" — that could be the clinical trial costs, R&D, etc. But management doesn't explicitly frame it as "we are paying for a waiting period." They talk about cost reductions to ensure they can meet primary goals in 2024.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.